Standard practice and controversial issues in front-line therapy of acute promyelocytic leukemia

Miguel A. Sanz, Francesco Lo Coco

Research output: Contribution to journalArticle

Abstract

In addition to choosing a state-of-the-art regimen including all-trans retinoic acid and anthracycline chemotherapy, modern management of acute promyelocytic leukemia (APL) implies the adoption of appropriate supportive measures, rapid establishment of an accurate genetic diagnosis, correct assessment of response to therapy and evaluation of the risk of disease recurrence by molecular monitoring. However, the general consensus about this overall strategy for APL treatment still leaves room for debate. In the present article, we review the current standard practice and controversial issues in the treatment of patients with newly diagnosed APL, including the management of special situations such as elderly patients, children and pregnant women.

Original languageEnglish
JournalHaematologica
Volume90
Issue number6
Publication statusPublished - Jun 2005

Fingerprint

Acute Promyelocytic Leukemia
Anthracyclines
Tretinoin
Pregnant Women
Therapeutics
Recurrence
Drug Therapy

Keywords

  • ALK1
  • Angiogenesis
  • Hereditary hemorrhagic telangiectasia (HHT)
  • TGF-β1
  • VEGF

ASJC Scopus subject areas

  • Hematology

Cite this

Standard practice and controversial issues in front-line therapy of acute promyelocytic leukemia. / Sanz, Miguel A.; Lo Coco, Francesco.

In: Haematologica, Vol. 90, No. 6, 06.2005.

Research output: Contribution to journalArticle

@article{f2dbbfa5a3fb4b7b85efb1f687ddd41a,
title = "Standard practice and controversial issues in front-line therapy of acute promyelocytic leukemia",
abstract = "In addition to choosing a state-of-the-art regimen including all-trans retinoic acid and anthracycline chemotherapy, modern management of acute promyelocytic leukemia (APL) implies the adoption of appropriate supportive measures, rapid establishment of an accurate genetic diagnosis, correct assessment of response to therapy and evaluation of the risk of disease recurrence by molecular monitoring. However, the general consensus about this overall strategy for APL treatment still leaves room for debate. In the present article, we review the current standard practice and controversial issues in the treatment of patients with newly diagnosed APL, including the management of special situations such as elderly patients, children and pregnant women.",
keywords = "ALK1, Angiogenesis, Hereditary hemorrhagic telangiectasia (HHT), TGF-β1, VEGF",
author = "Sanz, {Miguel A.} and {Lo Coco}, Francesco",
year = "2005",
month = "6",
language = "English",
volume = "90",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Standard practice and controversial issues in front-line therapy of acute promyelocytic leukemia

AU - Sanz, Miguel A.

AU - Lo Coco, Francesco

PY - 2005/6

Y1 - 2005/6

N2 - In addition to choosing a state-of-the-art regimen including all-trans retinoic acid and anthracycline chemotherapy, modern management of acute promyelocytic leukemia (APL) implies the adoption of appropriate supportive measures, rapid establishment of an accurate genetic diagnosis, correct assessment of response to therapy and evaluation of the risk of disease recurrence by molecular monitoring. However, the general consensus about this overall strategy for APL treatment still leaves room for debate. In the present article, we review the current standard practice and controversial issues in the treatment of patients with newly diagnosed APL, including the management of special situations such as elderly patients, children and pregnant women.

AB - In addition to choosing a state-of-the-art regimen including all-trans retinoic acid and anthracycline chemotherapy, modern management of acute promyelocytic leukemia (APL) implies the adoption of appropriate supportive measures, rapid establishment of an accurate genetic diagnosis, correct assessment of response to therapy and evaluation of the risk of disease recurrence by molecular monitoring. However, the general consensus about this overall strategy for APL treatment still leaves room for debate. In the present article, we review the current standard practice and controversial issues in the treatment of patients with newly diagnosed APL, including the management of special situations such as elderly patients, children and pregnant women.

KW - ALK1

KW - Angiogenesis

KW - Hereditary hemorrhagic telangiectasia (HHT)

KW - TGF-β1

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=21244446981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244446981&partnerID=8YFLogxK

M3 - Article

C2 - 15951298

AN - SCOPUS:21244446981

VL - 90

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 6

ER -